Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of ipatasertib with atezolizumab and paclitaxel in locally advanced unresectable or metastatic triple-negative breast cancer
MOH_2020-01-20_008515Phase 3Not yet recruiting
- Sponsor
- Roche
- Start
- Dec 2019
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ipatasertib, atezolizumab and paclitaxel in triple-negative breast cancer (TNBC) (3 arms), sponsored by Roche. Planned start Dec 2019; status: not yet recruiting.
02
Drugs
ipatasertibatezolizumabpaclitaxel
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on MOH_2020-01-20_008515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-01-20_008515.